Literature DB >> 22435384

Eculizumab and refractory membranoproliferative glomerulonephritis.

Seetha Radhakrishnan, Andrew Lunn, Michael Kirschfink, Paul Thorner, Diane Hebert, Valerie Langlois, Fred Pluthero, Christoph Licht.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22435384     DOI： 10.1056/NEJMc1106619

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  48 in total

1.  Glomerular disease: Eculizumab for the treatment of MPGN.

Authors:  Susan J Allison
Journal:  Nat Rev Nephrol       Date:  2012-04-10       Impact factor: 28.314

2.  Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe.

Authors:  A J Turley; B Gathmann; C Bangs; M Bradbury; S Seneviratne; L I Gonzalez-Granado; S Hackett; N Kutukculer; H Alachkar; S Hambleton; H Ritterbusch; P Kralickova; L Marodi; M G Seidel; G Dueckers; J Roesler; A Huissoon; H Baxendale; J Litzman; P D Arkwright
Journal:  J Clin Immunol       Date:  2015-02-08       Impact factor: 8.317

Review 3.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

4.  Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Authors:  Caroline Rousset-Rouvière; Mathilde Cailliez; Florentine Garaix; Daniele Bruno; Daniel Laurent; Michel Tsimaratos
Journal:  Pediatr Nephrol       Date:  2014-01-10       Impact factor: 3.714

5.  Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.

Authors:  Marie Nakano; Kazunori Karasawa; Takahito Moriyama; Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2019-03-11       Impact factor: 2.801

Review 6.  Update on membranoproliferative GN.

Authors:  Naveed Masani; Kenar D Jhaveri; Steven Fishbane
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 7.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

Review 8.  Targeting the complement cascade: novel treatments coming down the pike.

Authors:  Joshua M Thurman; Moglie Le Quintrec
Journal:  Kidney Int       Date:  2016-06-18       Impact factor: 10.612

Review 9.  Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

Authors:  Andrew S Bomback; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

Review 10.  Primary disease recurrence—effects on paediatric renal transplantation outcomes.

Authors:  Justine Bacchetta; Pierre Cochat
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.